Breaking News Instant updates and real-time market news.

CYTR

CytRx

$0.56

-0.0079 (-1.40%)

07:02
11/29/16
11/29
07:02
11/29/16
07:02

CytRx reports 'positive' results from Phase 3 Aldoxorubicin trial

CytRx announced positive updated results from its pivotal Phase 3 clinical trial evaluating aldoxorubicin compared to investigator's choice in patients with relapsed or refractory soft tissue sarcomas. The study, which enrolled 433 patients, demonstrated a statistically significant improvement in progression-free survival between aldoxorubicin and investigator's choice therapy in 246 patients with leiomyosarcoma and liposarcoma, (p=0.007). The hazard ratio was 0.62 (95% CI 0.44-0.88), representing a 38% reduction in the risk of tumor progression for patients receiving aldoxorubicin versus investigator's choice. Leiomyosarcoma and liposarcoma are the two most common types of STS and accounted for 57% of the patients enrolled in the trial. Aldoxorubicin demonstrated a statistically significant improvement in PFS over investigator's choice in 312 patients treated in North America (p=0.028; HR=0.71, 95% CI 0.53-0.97). Notably, aldoxorubicin performed better than investigator's choice for the entire study population and narrowly missed statistical significance (p=0.12; HR=0.81, 95% CI 0.64-1.06). All responses were determined by an independent, blinded central lab assessment of scans. CytRx plans to submit the results of this clinical trial for presentation at an upcoming major scientific meeting.

CYTR CytRx
$0.56

-0.0079 (-1.40%)

01/07/16
JEFF
01/07/16
INITIATION
Target $3
JEFF
Hold
CytRx initiated with a Hold at Jefferies
Jefferies analyst Chris Howerton started CytRx with a Hold rating and $3 price target. The stock is fairly valued given the opportunity for Aldoxorubicin in 2nd-line soft tissue sarcoma, the analyst tells investors in a research note.
01/07/16
01/07/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Agilent (A) initiated with a Hold at Deutsche Bank... Alexion (ALXN) initiated with a Buy at SunTrust... Alibaba (BABA) initiated with an Outperform at Baird... Bruker (BRKR) initiated with a Market Perform at Avondale... Care Capital Properties (CCP) initiated with a Neutral at Mizuho... Celgene (CELG) initiated with a Buy at SunTrust... Cepheid (CPHD) initiated with an Outperform at Avondale... Community Bank System (CBU) initiated with a Neutral at Piper Jaffray... CytRx (CYTR) initiated with a Hold at Jefferies... Del Taco (TACO) initiated with a Buy (yesterday) at BTIG... Depomed (DEPO) initiated with a Neutral at Mizuho... Ensco (ESV) initiated with an Equal Weight at Stephens... FCB Financial (FCB) initiated with a Buy at Gabelli... FactSet (FDS) initiated with a Hold at Evercore ISI... Fluidigm (FLDM) initiated with a Buy at Deutsche Bank... GTT Communications (GTT) initiated with an Overweight at Stephens... IBERIABANK (IBKC) initiated with a Neutral at Piper Jaffray... Illumina (ILMN) initiated with a Hold at Deutsche Bank... InspireMD (NSPR) initiated with a Buy at Rodman & Renshaw... Johnson Controls (JCI) initiated with an Outperform at Oppenheimer... McGraw Hill Financial (MHFI) initiated with a Buy at Evercore ISI... Moody's (MCO) initiated with a Hold at Evercore ISI... Myriad Genetics (MYGN) initiated with a Buy at Deutsche Bank... NBT Bancorp (NBTB) initiated with a Neutral at Piper Jaffray... Omnicell (OMCL) initiated with a Buy at Benchmark... Ophthotech (OPHT) initiated with a Buy at SunTrust... Paycom (PAYC) initiated with an Outperform at Baird... Paylocity (PCTY) initiated with an Outperform at Baird... PerkinElmer (PKI) initiated with a Hold at Deutsche Bank... Rowan Companies (RDC) initiated with an Equal Weight at Stephens... Shopify (SHOP) initiated with an Outperform at Baird... Syngenta (SYT) initiated with a Neutral at Macquarie... Thermo Fisher (TMO) initiated with a Buy at Deutsche Bank... Trovagene (TROV) initiated with a Market Perform at Avondale... UTi Worldwide (UTIW) to host special shareholder meeting... Waters (WAT) initiated with a Hold at Deutsche Bank... Wayfair (W) initiated with a Neutral at Baird... Willis Towers Watson (WLTW) initiated with an Underweight at JPMorgan.
07/12/16
FBRC
07/12/16
NO CHANGE
Target $3
FBRC
Outperform
CytRx price target lowered to $3 from $8 at FBR Capital
FBR Capital analyst Christopher James cut his price target for CytRx to $3 after the company's Phase III study with aldoxorubicin in patients with relapsed or refractory soft-tissue sarcoma was unable to meet its primary endpoint. Despite missing on the endpoint, aldoxorubicin demonstrated clear clinical activity, with an objective response rate nearly double the rate observed within the comparator arm, James tells investors in a research note. He keeps an Outperform rating on CytRx. In pre-market trading, the stock is down 69% to 77c.
07/12/16
JEFF
07/12/16
NO CHANGE
Target $0.75
JEFF
Hold
CytRx price target lowered to 75c from $2.50 at Jefferies
Jefferies analyst Chris Howerton cut his price target for CytRx to 75c from $2.50 after removing aldoxorubicin from his model following today's study failure. The analyst does not see a path forward for the drug in soft tissue sarcomas or any other indications. He keeps a Hold rating on the name. FBR Capital analyst Christopher James said this morning that despite missing on the endpoint, aldoxorubicin demonstrated clear clinical activity, with an objective response rate nearly double the rate observed within the comparator arm. CytRx is down 62% to 95c in late morning trading.

TODAY'S FREE FLY STORIES

SBUX

Starbucks

$57.21

-1.3 (-2.22%)

17:09
12/04/16
12/04
17:09
12/04/16
17:09
Conference/Events
Starbucks to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CS

Credit Suisse

$13.39

-0.34 (-2.48%)

17:03
12/04/16
12/04
17:03
12/04/16
17:03
Conference/Events
Credit Suisse to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

, SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

17:02
12/04/16
12/04
17:02
12/04/16
17:02
Hot Stocks
Takeda Pharma, Seattle Genetics reports Phase 3 ADCETRIS data »

Takeda Pharmaceutical…

TKPYY

Takeda Pharmaceutical Co. Ltd.

$20.40

0.135 (0.67%)

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CGEN

Compugen

$5.95

0.1 (1.71%)

16:59
12/04/16
12/04
16:59
12/04/16
16:59
Conference/Events
Compugen to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

QURE

uniQure

$5.68

-0.31 (-5.18%)

16:56
12/04/16
12/04
16:56
12/04/16
16:56
Hot Stocks
uniQure reports data on AMT-060 in hemophilia B »

uniQure announced new and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 08

    Dec

RGLS

Regulus

$2.50

0.1 (4.17%)

16:53
12/04/16
12/04
16:53
12/04/16
16:53
Conference/Events
Regulus to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 14

    Dec

PBI

Pitney Bowes

$14.63

0.1 (0.69%)

16:52
12/04/16
12/04
16:52
12/04/16
16:52
Conference/Events
Pitney Bowes to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:43
12/04/16
12/04
16:43
12/04/16
16:43
Hot Stocks
Seattle Genetics reports Phase 1b vadastuximab talirine data, plans Ph. 2 trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

16:38
12/04/16
12/04
16:38
12/04/16
16:38
Hot Stocks
Novartis reports Phase 2 SEG101 data »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PFE

Pfizer

$31.63

0.17 (0.54%)

16:33
12/04/16
12/04
16:33
12/04/16
16:33
Hot Stocks
Pfizer reports Phase 2 glasdegib data »

Pfizer announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

EKSO

Ekso Bionics

$4.27

-0.11 (-2.51%)

16:30
12/04/16
12/04
16:30
12/04/16
16:30
Conference/Events
Ekso Bionics to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ADSK

Autodesk

$70.57

1.35 (1.95%)

16:24
12/04/16
12/04
16:24
12/04/16
16:24
Conference/Events
Autodesk to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 09

    Jan

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

16:23
12/04/16
12/04
16:23
12/04/16
16:23
Hot Stocks
Seattle Genetics reports Phase 2 ADCETRIS lymphoma data, says discontinues trial »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

FTI

FMC Technologies

$35.60

0.9 (2.59%)

, TKPPY

Technip

$17.80

0.45 (2.59%)

16:21
12/04/16
12/04
16:21
12/04/16
16:21
Conference/Events
Technip to host special shareholder meeting »

Special Shareholder…

FTI

FMC Technologies

$35.60

0.9 (2.59%)

TKPPY

Technip

$17.80

0.45 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

TKPPY

Technip

$17.80

0.45 (2.59%)

, FTI

FMC Technologies

$35.60

0.9 (2.59%)

16:14
12/04/16
12/04
16:14
12/04/16
16:14
Conference/Events
FMC Technologies to host special shareholder meeting »

Special Shareholder…

TKPPY

Technip

$17.80

0.45 (2.59%)

FTI

FMC Technologies

$35.60

0.9 (2.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

16:04
12/04/16
12/04
16:04
12/04/16
16:04
Hot Stocks
Alnylam reports interim Phase 1 data on fitusiran »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADRO

Aduro Biotech

$10.80

0.25 (2.37%)

16:01
12/04/16
12/04
16:01
12/04/16
16:01
Hot Stocks
Aduro Biotech reports presentation of BION-1301 data »

Aduro Biotech announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRIL

Trillium Therapeutics

$6.70

-0.5 (-6.94%)

15:59
12/04/16
12/04
15:59
12/04/16
15:59
Hot Stocks
Trillium Therapeutics reports presentation of TTI-621 data »

Trillium Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

BLUE

bluebird bio

$69.75

1.1 (1.60%)

15:47
12/04/16
12/04
15:47
12/04/16
15:47
Hot Stocks
bluebird bio reports new data from HGB-205 study of LentiGlobin »

bluebird bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLCM

Bellicum Pharmaceuticals

$18.72

1.74 (10.25%)

15:43
12/04/16
12/04
15:43
12/04/16
15:43
Hot Stocks
Bellicum Pharmaceuticals reports updated data from BPX-501 study »

Bellicum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

15:39
12/04/16
12/04
15:39
12/04/16
15:39
Hot Stocks
Alnylam reports Phase 1 givosiran data, says plans Phase 3 study late 2017 »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$31.63

0.17 (0.54%)

, ONCE

Spark Therapeutics

$50.01

0.27 (0.54%)

15:32
12/04/16
12/04
15:32
12/04/16
15:32
Hot Stocks
Spark Therapeutics, Pfizer report updated preliminary data on SPK-9001 »

Spark Therapeutics (ONCE)…

PFE

Pfizer

$31.63

0.17 (0.54%)

ONCE

Spark Therapeutics

$50.01

0.27 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 06

    Dec

  • 06

    Dec

SGEN

Seattle Genetics

$66.70

-0.01 (-0.01%)

15:26
12/04/16
12/04
15:26
12/04/16
15:26
Conference/Events
Seattle Genetics to hold an investor reception »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$27.20

-0.1 (-0.37%)

15:21
12/04/16
12/04
15:21
12/04/16
15:21
Conference/Events
Roche to hold an analyst meeting »

Analyst Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

15:17
12/04/16
12/04
15:17
12/04/16
15:17
Hot Stocks
Juno Therapeutics reports Phase 1 data on JCAR014 »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.